Loading...
Market
Will VTAMA Cream receive FDA approval for atopic dermatitis by September 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Organon Acquires Roivant's Dermavant for $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 11:36 AM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences ($ROIV), in a deal valued at $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The deal involves an upfront payment of $175 million, with additional payments up to $1.2 billion contingent on sales milestones and approval in atopic dermatitis. This acquisition underscores Organon's commitment to expanding its portfolio in dermatology.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
